Potential treatment aims to help muscles repair in people with DMD

16 October 2025

Our muscles get tiny injuries all the time, especially when we move around. Normally, the body fixes this damage. But in Duchenne muscular dystrophy (DMD), the body finds it hard to repair muscles properly, which leads to muscle weakness over time.

A potential treatment called SAT-3247 is being tested to help the body restart its muscle repair system.

In a small, early trial, five adults with DMD took SAT-3247 for 28 days. The treatment was found to be safe and didn’t cause serious side effects. Some people also showed stronger grip strength compared to what usually happens in DMD without treatment (from natural history data).

While this is encouraging, there is still more research needed to understand how well the treatment works. Also, as the trial was small and didn’t include a placebo (a dummy drug), it’s hard to tell if the changes were really caused by SAT-3247.

Now, the same participants can keep taking the treatment for 11 more months to help scientists learn more about it. More young people aged 16–25 will also be invited to join this part of the trial, called an open label extension. A bigger trial (called a phase 2 trial) with a placebo is being planned to help confirm the results.